Research Use Only (RUO) Disclaimer: Semax, Selank, and Dihexa are research peptides not approved by the FDA, EMA, or any equivalent regulatory body for human therapeutic use. All information in this article is for educational and scientific research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a licensed healthcare provider before any human use.

Cognitive Peptide Research Stack 2026: Semax + Selank + Dihexa Protocol Guide

The Semax + Selank + Dihexa combination has emerged as one of the most discussed nootropic peptide research stacks, pairing three mechanistically distinct neuropeptides that together address complementary dimensions of cognitive biology: neurotrophin upregulation, anxiolytic modulation, and direct synaptogenesis promotion. Where most cognitive enhancement research focuses on single compounds, the rationale for combining these three lies in their non-overlapping mechanisms — each targets a different node in the neural plasticity cascade.

This guide covers the mechanistic rationale for each compound, the research-based logic for combining them, what the literature reports about dosing and administration, potential interactions, and how this stack compares to simpler two-compound approaches. For individual compound profiles, see the dedicated Semax research profile, Selank research profile, and Dihexa research profile. To design a protocol for your research, use the peptide stack builder or the peptide dosing calculator.

The Three-Compound Rationale: Why These Peptides Together

Understanding the Semax + Selank + Dihexa stack requires understanding what each compound does independently and why their mechanisms are synergistic rather than redundant.

Semax operates primarily through the BDNF/TrkB axis. A pivotal study by Dolotov et al. (2006) demonstrated that a single administration of Semax produced a 1.4-fold increase in BDNF protein levels and a threefold increase in BDNF mRNA expression in the rat hippocampus, alongside a 1.6-fold increase in TrkB tyrosine phosphorylation (PMID: 16996037). BDNF is often described as the primary neurotrophin governing synaptic plasticity, learning consolidation, and neuronal survival in the hippocampus and cortex. By upregulating both the neurotrophin and its receptor simultaneously, Semax activates downstream cascades including MAPK/ERK, PI3K/Akt, and PLC-gamma — pathways that support long-term potentiation (LTP) and new synapse formation.

Selank addresses a different dimension: anxiolytic-nootropic balance. In a clinical study comparing Selank to medazepam (a benzodiazepine) in 62 patients with generalized anxiety disorder and neurasthenia, Selank demonstrated comparable anxiolytic efficacy with additional antiasthenic and psychostimulant effects not seen with the benzodiazepine (PMID: 18454096). Critically for cognitive research, classic anxiolytics like benzodiazepines impair memory formation as a side effect of their sedating GABAergic activity. Selank does not share this liability. Research has shown it modulates GABAergic neurotransmission through a benzodiazepine-adjacent mechanism — likely acting on benzodiazepine-binding sites without the cognitive suppression — while also influencing the serotonergic and enkephalinergic systems (PMID: 28293190). In a nootropic stack, Selank functions as the anxiolytic anchor: reducing stress-cortisol load, which itself impairs hippocampal plasticity, while preserving or enhancing the consolidation environment for learning.

Dihexa represents the third and most structurally novel mechanism. Derived from angiotensin IV at Washington State University, Dihexa (PNB-0408) binds hepatocyte growth factor (HGF) with exceptionally high affinity — in the picomolar range — and potentiates its activation of the c-Met receptor tyrosine kinase. The HGF/c-Met signaling axis plays a well-established role in hippocampal neuroplasticity, dendritic arborization, and synapse formation. Animal studies demonstrated Dihexa's ability to increase dendritic spine density and restore cognitive performance in aged rodents with naturally occurring memory decline. A 2015 review described the brain HGF/c-Met system as a promising target for Alzheimer's disease and age-related cognitive decline (PMID: 25649658). Importantly, Dihexa's mechanism is entirely upstream of and independent from BDNF — it drives synaptogenesis through structural remodeling of synaptic networks, not neurotrophin signaling — meaning it adds to rather than duplicates Semax's effect.

Mechanistic Synergy: How the Three-Compound Stack Works Together

The three-peptide combination addresses cognitive biology at three distinct levels that are mutually reinforcing:

Level 1 — Neurotrophin supply (Semax): Upregulates BDNF and TrkB, creating the molecular environment favorable for LTP and new synapse formation. BDNF is the permissive signal for structural plasticity.

Level 2 — Structural synaptogenesis (Dihexa): Directly promotes dendritic spine formation and synaptic density through HGF/c-Met activation. While Semax creates the neurotrophin environment, Dihexa drives the physical construction of new synaptic connections. The two mechanisms converge on PI3K/Akt signaling from different upstream entry points, potentially producing additive downstream effects on synaptic growth machinery.

Level 3 — Stress attenuation (Selank): Chronic stress and elevated cortisol are among the most potent suppressors of hippocampal neurogenesis and BDNF expression. By providing anxiolytic coverage without sedation, Selank reduces the glucocorticoid-mediated brake on plasticity. The result is an improved signal-to-noise ratio: the pro-plasticity signals from Semax and Dihexa operate in a lower-cortisol environment created by Selank.

This layer-cake logic — supply the signal, build the structure, remove the inhibitor — is the core rationale for the three-compound approach over simpler single- or two-compound protocols.

Semax: ACTH(4-10) Analogue and BDNF Upregulator

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide developed in Russia as an analogue of the ACTH(4-7) core sequence with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. It is administered intranasally, reaching CNS targets rapidly through the olfactory pathway without significant systemic exposure.

The BDNF-upregulating effect follows a rapid time course. A time-course study tracking NGF and BDNF gene expression after Semax administration showed increases in both neurotrophins in the hippocampus, frontal cortex, and retina at multiple time points post-administration (PMID: 19662538). This pharmacodynamic profile makes Semax well-suited for acute pre-session administration in cognitive research settings. Beyond BDNF, Semax has demonstrated neuroprotective properties in ischemia-reperfusion models, including suppression of MMP-9 and inflammatory signaling, suggesting broad-spectrum neuroprotective activity that extends beyond simple neurotrophin upregulation.

In research models, Semax is typically studied at doses ranging from 25 to 300 micrograms intranasally, with single-administration studies producing measurable BDNF changes at 50 mcg/kg in rodents. The compound is supplied as a lyophilized powder for reconstitution with bacteriostatic water or sterile saline prior to intranasal delivery. For reconstitution math, see the peptide dosing calculator.

Selank: Tuftsin Analogue Anxiolytic-Nootropic

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from tuftsin — an endogenous tetrapeptide produced from IgG immunoglobulin — with a C-terminal Pro-Gly-Pro extension that improves its metabolic stability and CNS access. The peptide was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has a documented history of clinical research in Russia dating to the 1990s.

Selank's mechanism involves three intersecting systems. In the GABAergic system, research indicates Selank can compete for benzodiazepine binding sites on GABA-A receptors, modulating inhibitory tone through a mechanism distinct from classical benzodiazepines — producing anxiolytic effects without the sedation, muscle relaxation, or anticonvulsant properties that make benzodiazepines cognitively impairing (PMID: 28293190). In the serotonergic system, Selank influences monoamine metabolism and gene expression, contributing to mood stabilization. In the enkephalinergic system, Selank slows the enzymatic degradation of leu-enkephalin, prolonging the activity of these endogenous neuropeptides that regulate pain, stress, and emotional tone (PMID: 18454096).

In the context of a cognitive research stack, Selank's most critical function is reducing the neuroendocrine burden of stress. Cortisol suppresses hippocampal BDNF expression and inhibits the very neuroplasticity mechanisms that Semax and Dihexa attempt to activate. By modulating the anxiety response without impairing cognition, Selank creates a permissive environment for the pro-plasticity effects of its stack partners.

Dihexa: HGF/c-Met Agonist and Synaptogenesis Promoter

Dihexa (also known as PNB-0408) is a metabolically stabilized angiotensin IV analogue developed at Washington State University's Pharmaceutical Sciences department. Unlike the Russian-origin peptides above, Dihexa emerged from a systematic structure-activity relationship optimization program aimed at creating a compound with high oral bioavailability and blood-brain barrier penetration while retaining the procognitive properties of the parent angiotensin IV series.

The HGF/c-Met mechanism makes Dihexa structurally unique in the nootropic peptide landscape. HGF is a pleiotropic growth factor that, in the CNS, supports dendritic arborization, synaptic formation, neuronal survival, and the structural remodeling associated with memory consolidation. C-Met, its receptor tyrosine kinase, is expressed throughout the hippocampus and cortex in patterns consistent with its role in learning and memory circuits. Dihexa binds HGF with picomolar affinity and potentiates its interaction with c-Met, effectively amplifying the endogenous HGF signal without acting as a direct c-Met agonist.

In animal research, Dihexa restored spatial learning and memory performance in aged rodents and in scopolamine-induced cognitive impairment models, with molecular analysis confirming synaptogenesis as the structural correlate of the functional improvement. The synaptogenesis effect in hippocampal cell culture preparations was characterized as very potent at low concentrations. Researchers should note that the Dihexa literature is relatively limited and at least one key paper has received an Expression of Concern; independent replication remains an important outstanding step. A detailed review of Dihexa's research history is available at the Dihexa research profile.

Research Protocol Considerations

RUO Reminder: The following information reflects what is reported in the preclinical research literature. It does not constitute dosing recommendations for human use. These compounds are for laboratory research purposes only.

Research protocols for the three-compound stack must account for the different administration routes and onset kinetics of each compound. Semax and Selank are both administered intranasally in research models — a shared delivery route that simplifies protocol design. Dihexa is more complex: while animal studies demonstrated oral bioavailability, many research settings use subcutaneous administration for more controlled pharmacokinetics.

Semax in research models: Intranasal administration is the standard delivery method, with doses in rodent studies typically ranging from 50 to 300 mcg. Semax produces rapid CNS effects consistent with its olfactory pathway entry. Research cycle lengths in the literature vary from single-dose acute studies to multi-week protocols of 10 to 30 days. The compound is reconstituted from lyophilized powder with bacteriostatic water at concentrations appropriate for nasal administration volumes.

Selank in research models: Also administered intranasally. The anxiolytic effect in the clinical GAD study was observed across a defined treatment course. As with Semax, reconstitution from lyophilized powder is required; storage of the reconstituted solution follows standard peptide refrigeration practices.

Dihexa in research models: The compound's picomolar potency means research doses are substantially lower by mass than typical peptide quantities. Oral and subcutaneous routes have both been investigated in animal studies. For reconstitution calculations and dosing volume math, use the peptide dosing calculator.

Timing and sequencing: Given that Semax's BDNF upregulation peaks within hours of administration, research protocols using Semax as a morning intranasal administration and Selank at similar timing have been described in the literature. Dihexa's long duration of action (due to its structural modifications designed to extend half-life) may allow less frequent administration than the other two compounds. Formal studies of combined protocols have not been published; researchers should plan for appropriate washout periods and monitoring.

Comparison to Individual and Two-Compound Approaches

The three-compound stack is not universally appropriate for all research contexts. Single-compound studies provide cleaner mechanistic data. The three-compound approach is most appropriate for research aimed at characterizing combined functional outcomes rather than isolating individual mechanisms.

Two-compound protocols represent a middle ground. Semax + Selank is a well-established pairing in the Russian research literature. Semax + Dihexa without Selank removes the anxiolytic component, which may be appropriate for research contexts where stress modulation is not a variable of interest but synaptogenesis and neurotrophin effects are the primary endpoints. A dedicated comparison of all three compounds in individual cognitive profiles is available in the nootropic peptides comparison guide. For stack design assistance, see the stack builder tool.

Sourcing, Quality, and COA Considerations

All three compounds require lyophilized peptide sourcing from suppliers providing Certificates of Analysis with third-party HPLC purity data (greater than 98% by area under the curve) and mass spectrometry confirmation. Molecular weights for verification: Semax (887.0 Da), Selank (751.9 Da), and Dihexa (424.6 Da for the free base). Suppliers who cannot provide verified COA documentation with both HPLC and MS data should not be used for serious research applications. For sourcing comparison by supplier quality metrics, see the peptide supplier comparison pages.

Storage and Reconstitution

All three compounds follow standard lyophilized peptide storage protocols: -20°C for short-term storage, -80°C preferred for archival storage. Reconstituted solutions of Semax and Selank for intranasal use are maintained at 4°C and used within 4 to 6 weeks. Dihexa reconstituted solutions follow the same refrigeration guidelines. Avoid repeated freeze-thaw cycles after reconstitution. Use the peptide calculator for reconstitution math.

Conclusion

The Semax + Selank + Dihexa combination represents a mechanistically coherent approach to cognitive peptide research that targets three distinct but mutually reinforcing nodes in the neural plasticity cascade: BDNF upregulation via Semax, anxiolytic-nootropic balance via Selank, and direct synaptogenesis promotion via Dihexa's HGF/c-Met mechanism. The non-overlapping mechanisms provide a rational basis for combining these compounds in research settings, though formal studies of the combination as a unit remain limited.

Use the stack builder to plan your research protocol and the dosing calculator for reconstitution math. For individual compound context, see the Semax, Selank, and Dihexa research profiles.

Final RUO Disclaimer: Semax, Selank, and Dihexa are not approved by the FDA or any regulatory body for human therapeutic use. This article is for educational and research purposes only. Nothing in this guide constitutes medical advice or treatment recommendations. Always consult a licensed healthcare professional before any human use of research compounds.